2-(3-methoxybenzylamino)acetaldehyde dimethyl acetal | 53366-27-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-methoxybenzylamino)acetaldehyde dimethyl acetal
• 英文别名: N-(3-methoxybenzyl)aminoacetaldehyde dimethyl acetal；N-(3-Methoxy-benzyl)-aminoacetaldehyd-dimethylacetal；2,2-dimethoxy-N-[(3-methoxyphenyl)methyl]ethanamine
• CAS: 53366-27-1
• 化学式: C₁₂H₁₉NO₃
• mdl: MFCD12148388
• 分子量: 225.288
• InChiKey: FNJMAOQJBCDAEM-UHFFFAOYSA-N

物化性质

• 沸点：
  300.9±32.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3-methoxybenzylamino)acetaldehyde dimethyl acetal 在 cerium(III) chloride heptahydrate 、 硫酸 作用下， 以 水 、 乙腈 为溶剂， 反应 48.0h， 生成 1-(3-methoxybenzyl)benzo[f]indole-4,9-dione
  参考文献：
  名称：

  Ultrasound assisted one-pot synthesis of benzo-fused indole-4,9-dinones from 1,4-naphthoquinone and α-aminoacetals

  摘要：

  A one-pot synthesis of benzo[f]indole-4,9-diones from 1,4-naphthoquinone with alpha-aminoacetals has been developed. This method provides a straightforward synthesis of benzo[f]indole-4,9-diones via intramolecular nucleophilic attack of aminoquinones to aldehydes under mild reaction conditions. The detailed mechanism was also investigated. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2016.04.031
• 作为产物：
  描述：

  3-甲氧基苯甲醛 在 sodium tetrahydroborate 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 2-(3-methoxybenzylamino)acetaldehyde dimethyl acetal
  参考文献：
  名称：

  基于黄嘌呤的强效和选择性磷酸二酯酶抑制剂5

  摘要：

  PDE5抑制剂是治疗勃起功能障碍的有用治疗剂。已鉴定出一系列新的黄嘌呤衍生物作为PDE5的有效抑制剂，对其他PDE异构体（包括PDE6）具有良好的选择性。在狗中进行的研究表明，化合物21具有出色的口服生物利用度。

  DOI：

  10.1016/j.bmcl.2006.11.019

文献信息

• 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
  申请人：——

  公开号：US20030171384A1

  公开（公告）日：2003-09-11

  A compound of formula (I) in free or salt form, where R 1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R 2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino, R 3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R 4 is hydrogen or alkyl, R 5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl, a group of formula —N(R 6 )R 7 , aryl optionally substituted by one or more substituents selected from halogen or alkoxy, or heteroaryl having 5 or 6 ring atoms attached through a ring carbon atom to the indicated carbon atom, and R 6 and R 7 are each independently hydrogen or alkyl optionally substituted by hydroxy or alkoxy or one of R 6 and R 7 is hydrogen and the other is acyl, or R 6 and R 7 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclyl group.

  化合物的结构式(I)在自由或盐形式下，其中R1为氢或烷基，可以选择地被羟基、烷氧基或烷硫基取代，R2为氢、烷基、羟基烷基、烷基羰基氧基烷基、烷氧基烷基、烷硫基烷基、烯基、环烷基烷基、杂环烷基烷基、芳基烷基，其中芳环可以选择地与一个5-成员杂环基团融合，或可以选择地被烷氧基、氨基、烷基氨基、二烷基氨基、酰胺基、卤素、羟基、氨基磺酰基、烷基氨基磺酰基、二烷基氨基磺酰基、烷基磺酰氨基或二烷基氨基磺酰氨基等一个或多个取代基取代，R3为氢或烷基，可以选择地被羟基、烷氧基或烷硫基取代，R4为氢或烷基，R5为喹啉基、异喹啉基或氧代二氢异喹啉基，可以选择地与一个5-成员杂环基团融合，并可以选择地被卤素、氰基、羟基、烷基、羟基烷基、烷氧基烷基、烷硫基烷基、烷氧基、烷硫基、烯基、烷氧羰基、炔基、羧基、酰基、一个结构式为—N(R6)R7的基团、可以选择地被卤素或烷氧基等一个或多个取代基取代的芳基，或者通过一个环碳原子连接到所指示的碳原子的5个或6个环原子的杂芳基，R6和R7分别独立地为氢或烷基，可以选择地被羟基或烷氧基取代，或者R6和R7中的一个为氢，另一个为酰基，或者R6和R7与它们连接的氮原子一起表示一个5-或6-成员杂环基团。
• Combinations
  申请人：——

  公开号：US20030114469A1

  公开（公告）日：2003-06-19

  The present invention relates to a pharmaceutical composition, comprising (a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one of the active ingredients selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A reductase inhibitors; (iii) an anti-hypertensive agent; and (iv) a serotonin reuptake inhibitor (SSRI) or, in each case, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of sexual dysfunction, hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, erectile dysfunction, coronary heart disease, hypertension, especially ISH, angina pectoris, myocardial infarction, stroke, vascular restenosis, endothelial dysfunction, impaired vascular compliance, congestive heart failure.

  本发明涉及一种药物组合物，包括(a) 磷酸二酯酶5抑制剂或其药用盐，以及(b) 来自以下组中选择的至少一种活性成分(i) 抗糖尿病药物；(ii) HMG-Co-A还原酶抑制剂；(iii) 抗高血压药物；和(iv) 血清素再摄取抑制剂（SSRI）或在每种情况下，其药用盐；以及药学上可接受的载体。该药物组合物可用于治疗性功能障碍、高血糖、高胰岛素血症、高脂血症、高甘油三酯血症、糖尿病、胰岛素抵抗、糖代谢受损、糖耐量受损（IGT）病状、空腹血糖受损病状、肥胖、糖尿病视网膜病、糖尿病肾病、肾小球硬化、糖尿病神经病变、X综合征、勃起功能障碍、冠心病、高血压，尤其是高收缩压高血压（ISH），心绞痛、心肌梗死、中风、血管再狭窄、内皮功能障碍、血管顺应性受损、充血性心力衰竭。
• Synthesis of 1,2-Dihydroisoquinolines by a Modified Pomeranz–Fritsch Cyclization
  作者：Xiang Ji、Zheng Huang、Jean-Philip Lumb

  DOI：10.1021/acs.joc.9b02987

  日期：2020.1.17

  Isoquinolines (IQs) and their derivatives are present in many natural products and biologically active small molecules. Herein, we report a modified procedure for the classical Pomeranz-Fritsch protocol, which expands the scope of 1,2-dihydroisoquinoline (DHIQ) products. 1,2-DHIQs are an attractive branch point for the synthesis of IQs, but because of their innate reactivity, they have remained difficult

  异喹啉（IQ）及其衍生物存在于许多天然产物和具有生物活性的小分子中。在此，我们报告了经典Pomeranz-Fritsch协议的修改程序，该程序扩展了1,2-二氢异喹啉（DHIQ）产品的范围。1,2-DHIQ是合成IQ的一个有吸引力的分支点，但是由于其先天的反应性，它们仍然很难制备。我们证明了结合三甲基甲硅烷基三氟甲磺酸酯（TMSOTf）和胺碱的Fujioka / Kita条件，可以在足够温和的条件下活化Pomeranz-Fritsch环化所需的二甲基缩醛，以制备各种1,2-DHIQ产品。我们还通过进一步功能化为还原的四氢异喹啉（THIQ）或完全芳香化的IQ天然产品来证明这些DHIQ的合成价值。
• 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
  申请人：Bhalay Gurdip

  公开号：US20060106214A1

  公开（公告）日：2006-05-18

  A compound of formula (I) R 1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R 2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsufonylamino or dialkylaminosulfonylamino, R 3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R 4 is hydrogen or alkyl, R 5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl, a group of formula —N(R 6 )R 7 , aryl optionally substituted by one or more substituents selected from halogen or alkoxy, or heteroaryl having 5 or 6 ring atoms attached through a ring carbon atom to the indicated carbon atom, and R 6 and R 7 are each independently hydrogen or alkyl optionally substituted by hydroxy or alkoxy or one of R 6 and R 7 is hydrogen and the other is acyl, or R 6 and R 7 together with the nitrogen atom to which they are attached denote a 5- or 6- membered heterocyclyl group.

  化合物的式子（I）中，R1是氢或烷基，可以选择性地被羟基、烷氧基或烷基硫代取代，R2是氢、烷基、羟基烷基、烷基羧酸酯基、烷氧基烷基、烷基硫代烷基、烯基、环烷基烷基、杂环烷基烷基、芳基烷基，其中芳环可以选择性地与5元杂环基融合或可以选择性地被一种或多种取代基所取代，这些取代基包括烷氧基、氨基、烷基氨基、二烷基氨基、酰胺基、卤素、羟基、氨基磺酰基、烷基氨基磺酰基、二烷基氨基磺酰基、烷基磺酰氨基或二烷基氨基磺酰氨基，R3是氢或烷基，可以选择性地被羟基、烷氧基或烷基硫代取代，R4是氢或烷基，R5是喹啉基、异喹啉基或氧代二氢异喹啉基，可以选择性地与5元杂环基融合并可以选择性地被一种或多种取代基所取代，这些取代基包括卤素、氰基、羟基、烷基、羟基烷基、烷氧基烷基、烷基硫代烷基、烷氧基、烷基硫代基、烯基、烷氧羰基、炔基、羧基、酰基、式子-N（R6）R7的基团、芳基，其中芳基可以选择性地被一种或多种取代基所取代，这些取代基包括卤素或烷氧基，或者是通过一个环碳原子与所指定的碳原子相连的含有5个或6个环原子的杂环芳基，R6和R7各自独立地是氢或烷基，可以选择性地被羟基或烷氧基取代，或者R6和R7中的一个是氢，另一个是酰基，或者R6和R7连同它们所附着的氮原子一起表示一个含有5个或6个环原子的杂环基团。
• 8-Quinolinxanthine and 8-isoquinolinxant hine derivatives as PDE 5 inhibitors
  申请人：——

  公开号：US20040038996A1

  公开（公告）日：2004-02-26

  A compound of formula (I) 1 R 1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R 2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino or dialkylaminosulfonylamino, R 3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R 4 is hydrogen or alkyl, R 5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl, a group of formula —N(R 6 )R 7 , aryl optionally substituted by one or more substituents selected from halogen or alkoxy, or heteroaryl having 5 or 6 ring atoms attached through a ring carbon atom to the indicated carbon atom, and R 6 and R 7 are each independently hydrogen or alkyl optionally substituted by hydroxy or alkoxy or one of R 6 and R 7 is hydrogen and the other is acyl, or R 6 and R 7 together with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclyl group.

  化合物的化学式（I）：其中，1R1为氢或烷基，可以选择性地被羟基，烷氧基或烷基硫代取代；R2为氢，烷基，羟基烷基，烷氧基烷基羰基氧基烷基，烷基硫代烷基，烯基，环烷基烷基，杂环基烷基，芳基烷基，其中其芳环可以选择性地与5元杂环基融合或可以选择性地被一个或多个取代基所取代，所述取代基被选择自烷氧基，氨基，烷基氨基，二烷基氨基，酰胺基，卤素，羟基，氨基磺酰基，烷基氨基磺酰基，二烷基氨基磺酰基，烷基磺酰氨基或二烷基氨基磺酰氨基；R3为氢或烷基，可以选择性地被羟基，烷氧基或烷基硫代取代；R4为氢或烷基；R5为喹啉基，异喹啉基或氧代二氢异喹啉基，可以选择性地与5元杂环基融合，并且可以选择性地被一个或多个取代基所取代，所述取代基被选择自卤素，氰基，羟基，烷基，羟基烷基，烷氧基烷基硫代烷基，烷氧基，烷基硫代基，烯基，烷氧羰基，炔基，羧基，酰基，式为—N（R6）R7的基团，可以选择性地被一个或多个取代基所取代，所述取代基被选择自卤素或烷氧基的芳基，或者具有5个或6个环原子的杂环芳基，通过一个环碳原子与所示碳原子相连，其中R6和R7各自独立地为氢或烷基，可以选择性地被羟基或烷氧基取代，或者R6和R7中的一个为氢，另一个为酰基，或者R6和R7与它们所附着的氮原子一起表示一个5元或6元杂环基团。